LL-37
Antimicrobial
Also known as: Cathelicidin, CAP18
The only human cathelicidin antimicrobial peptide, providing broad-spectrum antimicrobial activity and immunomodulatory effects.
- Dose in studies
- 50-100 mcg per day
- Frequency
- Daily during infection/healing
- Cycle length
- Until infection resolved, typically 1-2 weeks
- Half-life
- 15-30 minutes
- Research level
- 2/5 – Limited research
Frequently asked questions about LL-37
What is LL-37?
The only human cathelicidin antimicrobial peptide, providing broad-spectrum antimicrobial activity and immunomodulatory effects.
What is the half-life of LL-37?
The half-life of LL-37 is 15-30 minutes.
What dosage of LL-37 has been studied?
Described in research: 50-100 mcg per day, frequency: Daily during infection/healing. This is not a medical recommendation.
How long is a LL-37 cycle?
Typical cycle length in studies: Until infection resolved, typically 1-2 weeks.
What are the side effects of LL-37?
Injection site reactions: Redness, swelling, and soreness at injection site. The most common side effect. May be more pronounced than with other peptides due to LL-37's immune-activating properties. · Local inflammation: Mild inflammatory response at application site. This is part of the mechanism of action and indicates immune activation. · Mild fever: Low-grade temperature elevation as immune…
How well researched is LL-37?
Limited research (2/5). Few, small or uncontrolled human data; mostly animal studies.